Please login to the form below

Not currently logged in
Email:
Password:

drug reimbursement

This page shows the latest drug reimbursement news and features for those working in and with pharma, biotech and healthcare.

Chi-Med cues up two more regulatory filings in cancer

Chi-Med cues up two more regulatory filings in cancer

in the China National Reimbursement Drug List (NRDL) at the next update later this year. ... Within two years, To expects Chi-Med to become “a fully integrated and globally-facing biopharmaceutical company with capability to discover, develop and

Latest news

  • Orphan drugs market to soar to $224bn by 2024 Orphan drugs market to soar to $224bn by 2024

    orphan drug product in 2024, and will help bring in total orphan drug sales of $13.7bn for the company. ... in 2018 versus $33, 654 for a non-orphan drug, explain much of the allure,” says the report.

  • Urovant slips on phase 3 incontinence drug data Urovant slips on phase 3 incontinence drug data

    As tolterodine is generically available that has raised questions about whether doctors would be prepared to prescribe vibegron – and moreover if insurers would back reimbursement of the drug – ahead of a ... If approved, it would become the first

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    Drug pricing and reimbursement remains at the forefront of pharma executive minds as 2019 gets underway, according to a new industry survey. ... Unphased by the data, Trump told a cabinet meeting this week that “you’re going to see a tremendous

  • Better together when buying medicines? Taking stock of the BeNeLuxA initiative Better together when buying medicines? Taking stock of the BeNeLuxA initiative

    Apply that to the fragmented and diverse landscape of drug pricing and reimbursement in Europe and the reality becomes a lot more complicated. ... There is MEDEV too, an informal cooperation on the assessment, pricing and reimbursement of medicines in

  • Vertex rises on data for cystic fibrosis triple therapy Vertex rises on data for cystic fibrosis triple therapy

    Company will wait for further results before filing. Vertex Pharma has unveiled the first phase 3 data from its highly-anticipated three-drug combination for cystic fibrosis (CF), setting up a ... The interim results come from two studies of its two-drug

More from news
Approximately 36 fully matching, plus 56 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest appointments

  • Extension for head of Germany’s VFA Extension for head of Germany’s VFA

    She has led the industry voice during an unsettled time for pharma in Germany with many companies critical of the AMNOG system of drug reimbursement introduced in 2010, which has seen

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics